Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

The “Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice,” authored by researchers from Truven Health Analytics, the National Pharmaceutical Council, Harvard Medical School and the University of Michigan, suggests that changes are needed to enable more consistent translation of research findings into clinical practice.

Study authors evaluated real-world utilization trends before and after the publication of comparative effectiveness research (CER) findings and the release of relevant clinical practice guidelines (CPGs) from four high-profile CER case studies published within the last decade.  

Analysis revealed no clear pattern of utilization in the first four quarters after publication. Even when research was included in revised or updated CPGs, researchers were not able to consistently find changes in utilization or clinical practice. More specifically:

  • PROVE-IT (2004). The PROVE-IT study compared standard and intensive cholesterol-lowering therapies and their impact on multiple cardiovascular-related outcomes. Study results showing a lower risk of death or cardiovascular events for those on intensive than on standard therapy were captured in accompanying CPGs, which would have led to predictions of a consequent increased use of intensive statin therapy and decreased use of standard statin therapy. In clinical practice, use of intensive therapy remained flat in the three years after study publication, prior to a decline in the use of standard therapy.

  • MAMMOGRAPHY WITH MAGNETIC RESONANCE IMAGING (MRI) (2004). The MRI -study compared the effectiveness of mammography, ultrasound, magnetic resonance imaging (MRI) and clinical breast exam in detecting tumors among carriers of BRCA1 or BRCA2 mutations. Strong study results favoring the use of MRI led to new CPGs. In clinical practice, while the use of MRI did increase prior to and after the result of findings and new guidelines, MRI utilization was far less than the utilization of ultrasound or mammography, which also increased or remained steady.

  • SPORT (2006). The Spine Patient Outcomes Research Trial (SPORT) compared whether surgery (standard open discectomy) was more effective than non-operative treatment for people with herniated disks. While the research results and CPGs that followed would have suggested an increase in the use of surgery, in clinical practice surgical rates over time remained steady.

  • COURAGE (2007). The COURAGE trial assessed whether adding percutaneous coronary intervention (PCI) to optimal medical therapy (OMT) for people with coronary artery disease improved outcomes. The research would have suggested either steady or decreased use of PCI, yet in clinical practice usage oscillated in the two years following research publication and updated CPGs.

Conclusions from the CER and clinical practice study suggest areas where continued effort is needed to effectively translate and disseminate CER results to improve application of CER in clinical practice.

  • Improve stakeholder engagement in research design and development. Progress can be seen in efforts to date by organizations like the Patient-Centered Outcomes Research Institute (PCORI), which has already yielded greater involvement from patients in determining which research questions need to be asked and answered.

  • Identify where multiple confirmatory studies are needed. Accumulating research can be particularly important when evidence is conflicting with current practice, or when the science is less mature.

  • Fund studies to confirm or shape clinical opinion or current practices. Fostering a learning health system can streamline efforts to identify where multiple confirmatory studies should result in changes to clinical practice.

  • Align financial incentives with evidence. As an example, as an alternative to rewarding volume of treatments, procedures and services,  there is promising work being done with value-based insurance design (V-BID), shared savings models and bundled, severity-adjusted payments.

  • Improve understanding of how to translate knowledge to different stakeholders. Growing research in the area of study referred to as ‘knowledge translation’ will help isolate the factors that move research into practice at the point of decision-making.

  • Coordinate dissemination and policy efforts. Clinical practice guidelines are a necessary first step to synthesize evidence and can serve as a catalyst for uptake, other dissemination efforts, such as media campaigns, targeted outreach and others, may be important components of evidence dissemination.

Blog Post

Tackling Data Access at Health Datapalooza

By Jennifer Graff, PharmD, NPC VP for Comparative Effectiveness ResearchWe’re looking forward to participating in Health Datapalooza next week, which...
Newsletter Volume

E.V.I.dently: April 2016

MessageValue Assessment Through a Broader, Patient-Focused LensNPC has developed “Guiding Practices for Patient-Centered Value Assessment” to help...
YouTube Videos

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

This one-hour webinar highlights the results of NPC's annual survey of comparative effectiveness research (CER) stakeholders and includes a panel...
Newsletter Volume

E.V.I.dently January 2016

MessageThe Importance of Evidence, Value, Access and Innovation in 2016In his annual health care outlook, NPC President Dan Leonard explains why...
Press Release

NPC Comments on CMS’ Announcement to Allow Broader Access to Publicly Funded Databases

(Washington, DC, June 2, 2015)—The National Pharmaceutical Council (NPC) today commented on the Centers for Medicare and Medicaid Services’ (CMS)...
Press Release

State Medicaid Directors Share Views on Comparative Effectiveness Research And Its Impact on Policy in National Pharmaceutical Council Survey

(Washington, DC, April 16, 2015)—A new survey conducted on behalf of the National Pharmaceutical Council (NPC) shows that state Medicaid directors...
Press Release

NPC Highlights Stakeholder Views on Comparative Effectiveness Research and the Environment for Health Care Decision-Making

(Washington, DC, March 26, 2015)—A new survey of health care stakeholders reveals continued optimism that comparative effectiveness research (CER)...
Press Release

NPC Study Outlines When & How Health Decision-Makers Should Consider Individual Patient Differences

Washington, DC (July 29, 2014)—New research led by the National Pharmaceutical Council (NPC) can assist health care stakeholders to understand when...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on PCORI Proposal for Peer Review of Primary Research and Public Release of Research Findings

November 7, 2014Dr. Joe SelbyExecutive DirectorPatient-Centered Outcomes Research Institute1828 L St., NW, Suite 900Washington, DC 20036Dear Dr....
Commentary and Testimony Page

The State of CER and the Environment for Health Care Decision Making

This month, NPC released its third annual survey on stakeholders’ views on comparative effectiveness research (CER), “The State of Comparative...
Commentary and Testimony Page

Keeping Our Eye on the CER Ball

Until the cherry blossoms begin to bloom later next month, most of the water cooler conversations in Washington will focus on the federal budget....
YouTube Videos

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

This one-hour webinar highlights the results of NPC's annual survey of comparative effectiveness research (CER) stakeholders and includes a panel...
YouTube Videos

Comparative Effectiveness Research and the Environment for Health Care Decision-Making

During a March 26, 2015 webinar, the National Pharmaceutical Council discussed the results of its annual stakeholder survey on comparative...
YouTube Videos

Access to Specialty Medications & Value-Based Insurance Design

Specialty medications have been making health care headlines because of their effectiveness and higher costs. How can we ensure that patients will...
YouTube Videos

Real-World Impact of Comparative Effectiveness Research Findings on Clinical Practice

National Pharmaceutical Council Chief Science Officer Robert W. Dubois, MD, PhD, discusses a peer-reviewed study suggesting that changes are needed...
Blog Post

Tackling Data Access at Health Datapalooza

By Jennifer Graff, PharmD, NPC VP for Comparative Effectiveness ResearchWe’re looking forward to participating in Health Datapalooza next week, which...
Blog Post

Key Considerations for Cost Effectiveness Thresholds

While putting a price tag on the value of health care services and the life years gained is common in countries including the United Kingdom, Canada...
Blog Post

CER Tweets of the Week: JCER Editorial on Treatment Sequences in Oncology; JNCCN Discusses CER Database Analyses (December 14-18, 2015)

What were comparative effectiveness research (CER) stakeholders talking about on Twitter this week? Popular topics included the Journal of...
Blog Post

#TBT: Value-Based Insurance Design & New Medicare Advantage Model

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research...
cersurvey16

2016 Comparative Effectiveness Research and the Environment for Health Care Decision-Making

NPC's sixth annual survey of stakeholder views on comparative effectiveness research (CER) and the...

Developing Evidence that is Fit for Purpose: A Framework for Payer and Research Dialogue

A study published in the September 2015 issue of The American Journal of Managed Care introduces a...
  •  
  • 1 of 15
  • >